Q2 Earnings Forecast for Quanterix Issued By Leerink Partnrs

Quanterix Corporation (NASDAQ:QTRX - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Quanterix in a research report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.45). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Quanterix's current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix's Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.87) EPS.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.16. The company had revenue of $30.33 million during the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative return on equity of 15.07% and a negative net margin of 36.82%.

A number of other research firms have also weighed in on QTRX. Scotiabank restated an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Wall Street Zen lowered Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Leerink Partners reiterated a "market perform" rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Finally, Canaccord Genuity Group decreased their price objective on Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $13.50.

Quanterix Stock Down 2.5%

Quanterix stock opened at $5.37 on Monday. The business has a fifty day moving average of $5.73 and a two-hundred day moving average of $6.83. The firm has a market cap of $268.23 million, a P/E ratio of -4.13 and a beta of 1.13. Quanterix has a twelve month low of $4.05 and a twelve month high of $16.01.

Institutional Investors Weigh In On Quanterix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after purchasing an additional 1,963 shares during the period. Jane Street Group LLC grew its position in shares of Quanterix by 4.2% during the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock valued at $380,000 after acquiring an additional 2,366 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after acquiring an additional 3,915 shares during the period. Hsbc Holdings PLC grew its position in shares of Quanterix by 25.8% during the 4th quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock valued at $205,000 after acquiring an additional 3,974 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in shares of Quanterix by 64.5% during the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after acquiring an additional 4,000 shares during the period. 86.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Quanterix news, Director David R. Walt purchased 123,990 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average price of $6.14 per share, for a total transaction of $761,298.60. Following the acquisition, the director owned 1,866,933 shares in the company, valued at $11,462,968.62. This represents a 7.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William P. Donnelly purchased 93,113 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $5.44 per share, for a total transaction of $506,534.72. Following the acquisition, the director owned 139,094 shares in the company, valued at $756,671.36. This trade represents a 202.50% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 463,113 shares of company stock worth $2,625,444. 6.90% of the stock is owned by insiders.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.